# Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

> **NCT07304739** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Furmonertinib
- **DRUG:** Intrathecal chemotherapy
- **RADIATION:** Stereotactic radiotherapy

## Key facts

- **NCT ID:** NCT07304739
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304739, "Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT07304739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*